Meriofert® Pfs

Follicle-Stimulating Hormone and Luteinising Hormone, the active ingredient in Meriofert® Pfs, is a gonadotropin presented as a sterile injectable solution for subcutaneous use. It is prescribed to treat infertility caused by anovulation and to replace deficient gonadotropins in hypogonadotropic hypogonadism. GNH USA supplies Meriofert® Pfs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert® Pfs is a gonadotropin used in reproductive‑endocrine disorders to restore or stimulate ovarian function. - Infertility due to anovulation: promotes follicular growth and induces ovulation. - Hypogonadotropic hypogonadism: replaces deficient FSH and LH to re‑establish normal ovarian activity. - Assisted reproductive technology cycles: supports controlled ovarian stimulation in IVF and ICSI protocols.

Common Side Effects: - Injection site pain or erythema: mild local reaction at the injection site. - Abdominal discomfort: transient bloating or mild cramping. - Headache: mild to moderate intensity. - Nausea: occasional upset stomach. - Breast tenderness: mild swelling or soreness. - Mild ovarian hyperstimulation syndrome (OHSS): mild abdominal distension.

Serious or Rare Side Effects: - Severe OHSS: rapid weight gain, ascites, or respiratory distress. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Allergic reactions: rash, itching, or anaphylaxis. - Pulmonary edema: fluid accumulation in lungs. - Ectopic pregnancy: implantation outside the uterus. - Multiple pregnancy: gestation of twins or higher order multiples.

Before initiating therapy, clinicians should assess patient history and monitor response closely. - Pregnancy testing: confirm the patient is not pregnant prior to starting treatment. - Ovarian monitoring: perform ultrasound to detect excessive follicular response. - Hormone levels: check baseline FSH, LH, and estradiol values. - Thrombotic risk: evaluate history of clotting disorders. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert® Pfs may interact with several drug classes that affect reproductive hormones or coagulation. Major Interactions (Avoid): - GnRH agonists: may amplify gonadotropin response, increasing OHSS risk. - GnRH antagonists: may blunt the intended effect of FSH/LH. - Ovarian stimulation agents (e.g., clomiphene): heightened risk of excessive ovarian response. - Steroid hormones: can alter endogenous hormone balance. - Anticoagulants: increased bleeding risk at injection sites.

Moderate Interactions (Monitor Closely): - Thyroid hormone therapy: monitor thyroid function tests. - Antidiabetic agents: observe glucose fluctuations. - NSAIDs: may mask pain from ovarian enlargement. - Antidepressants: watch for mood changes. - Herbal supplements (e.g., phytoestrogens): possible interference with hormone activity.